… 345 patent”), both relating to EYLEA® (aflibercept).  The ’865 … Bioepis and Formycon’s EYLEA® IPRs Discretionarily Denied Institution … aBLA filing with the FDA.  Unlike the Petitioners filing … related to its EYLEA® biosimilar. Regeneron reported EYLEA® U.S. …

… .S. sales of EYLEA HD and global sales … price targets on Regeneron Pharmaceuticals following earnings announcement. Trending … Yatin Suneja maintained Regeneron Pharmaceuticals with a Buy … Matthew Harrison maintained Regeneron Pharmaceuticals with an Overweight …

… delays for blockbuster ophthalmology drug Eylea HD due to problems … syringe and for the treatment of macular edema … observations made during the FDA inspection. Schleifer commented … you deserve! The Pharmaceutical Technology Excellence Awards celebrate …

… 2023 identified Eylea (aflibercept) as the second most expensive drug by total … expensive drug by total spending, costing more than $1 billion. Both Eylea … insurance. Among the eye treatments covered by traditional Medicare, 31% were switched …

… 156 weeks of the trial. The FDA approved Eylea HD for neovascular age … the PULSAR trial at its 48-week mark. The drug was … the data collected from those trials for evidence of the durability … to one of three groups: treatment with an 8-milligram injection …

… August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings … and only FDA-approved targeted medicine for bullous pemphigoid … cross-trial comparisons, patients taking a 4-drug combination … treatments to even more patients. Starting with EYLEA HD and EYLEA …

… trial that led to the FDA approval of Eylea HD as a treatment … Regeneron, the drug’s maker, markets as Eylea. The analysis showed … it lessens the burden of treatment — fewer injections and appointments … indication that the anti-VEGF drug is working. Data shared …

… explore how those clinical trials and use of Eylea HD are playing … treatment patterns of Eylea HD among patients with diabetic macular edema. The FDA … has approved Eylea HD as a treatment for diabetic macular …

… rundown of news involving Regeneron Pharmaceuticals and Allogene Therapeutics, as … FDA will delay a decision on an application for high-dose Eylea … to prepare patients for treatment with Allogene’s donor- … trials. It will move forward with a standard two-drug …

… FDA decisions due this month for its eye disease drug Eylea … of progress with its confirmatory trials. Problems for Regeneron at … quarter, Regeneron reported the Eylea franchise generated revenue of … syringe and for the treatment of macular edema following …